SUCCESSFUL TREATMENT OF FACIAL SYSTEMIC LUPUS ERYTHEMATOSUS LESIONS WITH DR MICHAELS® (SORATINEX®) PRODUCT FAMILY.
A CASE REPORT


1Psoriasis & Skin Clinic, Melbourne, Australia; 2nd Medical Faculty, Charles University, Bulovka Hospital, Prague, Czech Republic; 3Department of Nuclear Physics, Sub-nuclear and Radiation, G. Marconi University, Rome, Italy; 4Dermatological Department University of Pisa, Pisa, Italy; "Onkoderna" - Policlinic for dermatology and dermatologic surgery, Sofia, Bulgaria; 5Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria; 6Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria; 7Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany; 8PRO SANUM Ltd, Sanatorium of Prof. Novotný, Štěpánská Prague I, Czech Republic; 9University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India; 10Department of Medicinal Information and Non-interventional studies, Bulgarian Drug Agency, Sofia, Bulgaria; 11Department of Dermatology & Cutaneous Surgery, Department of Psychiatry & Behavioral Sciences, Institute for Bioethics & Health Policy, University of Miami, Miller School of Medicine, Miami, FL, USA; 12Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi “G. Marconi”, Rome, Italy; 13Chair of Dermatology, University of Rome “G. Marconi” Rome, Italy

Systemic lupus erythematosus (SLE) is a complex autoimmune disease in which the body’s immune system mistakenly attacks healthy tissue. It can affect the skin, joints, kidneys, brain and other organs. We report the case of a 7-year-old female patient with facial lesions of SLE since the age of 5. There was no significant family history and patient had been a healthy child from birth. The child presented with a malar rash, also known as a butterfly rash, with distribution over the cheeks but sparing the nasal bridge. This case represents the efficacy of the Dr. Michaels® (SoratineX®) product family in the successful resolution of facial lesions of SLE.